|  |  |  |  |
| --- | --- | --- | --- |
| **Indication** | **Primary n (%)** | **Secondary n (%)** | **Tertiary n (%)** |
| Anxiety | 302 (100%) |  | - |
| Agarophobia | - | 6 (1.99%) | 1 (0.33%) |
| Attention deficit hyperactivity disorder | - | 7 (2.32%) | 5 (1.66%) |
| Autistic spectrum disorder | - | 7 (2.32%) | 5 (1.66%) |
| Cancer pain | - | 1 (0.33%) | 0 (0.00%) |
| Chronic pain | - | 8 (2.65%) | 5 (1.66%) |
| Crohns | - | 1 (0.33%) | 0 (0.00%) |
| Depression | - | 75 (24.83%) | 10 (3.31%) |
| Eating disorder | - | 1 (0.33%) | 3 (0.99%) |
| Fibromyalgia | - | 3 (0.99%) | 0 (0.00%) |
| Headache | - | 1 (0.33%) | 0 (0.00%) |
| Insomnia | - | 11 (3.64%) | 12 (3.97%) |
| Neuropathic pain | - | 1 (0.33%) | 0 (0.00%) |
| OCD | - | 3 (0.99%) | 3 (0.99%) |
| Panic disorder | - | 5 (1.66%) | 0 (0.00%) |
| Parkinson's | - | 1 (0.33%) | 0 (0.00%) |
| PTSD | - | 7 (2.32%) | 5 (1.66%) |
| Social phobia | - | 4 (1.32%) | 1 (0.33%) |
| Ulcerative colitis  | - | 0 (0.00%) | 1 (0.33%) |
| **Total** | 302 (100%) | 142 (47.02%) | 52 (7.22%) |

***Supplementary Table 2. Indications for treatment with cannabis-based medicinal products.*** *Primary, secondary, and tertiary indications for cannabis based medicinal product treatment recorded by clinicians at baseline and throughout the treatment. Data is presented as n (%). n=302. PTSD = post-traumatic stress disorder, OCD = obsessive compulsive disorder.*